Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01529437 · ClinicalTrials.gov registry record · Phase 1
Sublingual Immunotherapy Studies for Grass and Dust Mite Allergies
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT01529437: Completed Phase 1 study, sponsored by Stanford University.
NCT01529437 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 31 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (48% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01529437, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
This is a study for children and adults who are interested in a new therapy for their allergies to dust mite and timothy grass. The new therapy is called sublingual immunotherapy and the investigators are testing if it is safe and well tolerated.
Primary Outcome
We will assess safety outcomes according to GCP/CFR and NIAID guidelines
Interventions
- DRUG sublingual immunotherapy
- DRUG placebo sublingual immunotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2005-01 |
| Est. Completion | 2014-01 |
| Phase | Phase 1 |
What the finished NCT01529437 record still lists
NCT01529437 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (48% lower).
The record links to 0 conditions, and to 2 interventions - of which sublingual immunotherapy is the first listed.
NCT01529437 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01529437 about?
NCT01529437 is a clinical study titled "Sublingual Immunotherapy Studies for Grass and Dust Mite Allergies". This is a study for children and adults who are interested in a new therapy for their allergies to dust mite and timothy grass. The new therapy is called sublingual immunotherapy and the investigators are testing if it is safe and well tolerated.
What is the current status of trial NCT01529437?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2005-01. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01529437?
The interventions under investigation include: sublingual immunotherapy (DRUG), placebo sublingual immunotherapy (DRUG).
Who is sponsoring clinical trial NCT01529437?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01529437's enrollment target sits among peer trials
31 1322nd of 2000 higher than 669 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia